In this paper,the safety and efficacy of 131I-labeled mouse/human chimeric monoclonal antibody(131I-chTNT)-mediated radioimmunotherapy are evaluated because the patients have non-uptaking 131I pulmonary metastases from differentiated thyroid carcinoma(DTC).The 16 patients were injected intravenously by 29.6±3.7MBq·kg–1 using 131I-chTNT.The chest computer tomography was performed before treatment,as well as 28 and 70days after treatment.Responses and safety were assessed during the treatment.The results show that the 131I-chTNT infusion was well tolerated with the 12.5%complete response,18.8%partial response,25.0%progressive disease,and the 43.8%stable disease,indicating that most treatment-related adverse effects are mild transient and reversible.The131I-chTNT is promising for patients with non-uptaking the 131I pulmonary metastases from DTC.
GAO ShiJI TiefengWEN QiangCHEN BinMA QingjieCHEN ZuoweiLIU Lin
The 99mTc-3PRGD2 targeted SPECT/CT scanning was of significance in detecting differentiated glioma.In this work,the diagnostic value of 99mTc-3PRGD2 scintigraphy in brain glioma was evaluated by the ten clinically verified brain glioma patients after obtaining informed consent.The patients first accepted X-ray imaging to localize the detecting regions before administrating with 99mTc-3PRGD2 at a mean radioactivity of 849±115 MBq via single intravenous bolus injection 2 h prior to SPECT/CT imaging.Tumor samples for detectingαvβ3 were collected by surgical operations two weeks after the scintigraphy.The results of CT and SPECT scanning were merged and compared.The correlation between tumor occupation（T/N ratio） andαvβ3 expression level were analyzed.The T/N ratios in brain glioma were proportionally correlated to av(33 positive cell percentage（R2=0.9253,p<0.05）.This study primarily evaluated the clinical application of 99mTc-3PRGD2 SPECT scintigraphy on brain glioma.The more pathological types and detecting strategies covering a large amount of samples would aid to clarify the potentials.
In recent years,several RGD(Arg-Gly-Asp)-based radiotracers have already been successfully tested in human for the visualization of integrin αvβ3,demonstrating its feasibility in tumor diagnosis.In this paper,we evaluated the 99mTc-3P4-RGD2 single photon emission computed tomography/computerized tomography(SPECT/CT)in patients suffering from space occupying disease of esophagus.40 patients(34 males and 6 female;mean age: 58.3 years) with a suspected space occupying lesion of esophagus were included,thus finally obtaining their definite pathologic diagnosis(malignant,n=32;benign,n=8).All patients underwent endoscopic,barium esophagography and SPECT/CT imaging preoperatively.The chest SPECT was performed at 4 h after administration of99mTc-3P4-RGD2 with a dose of 939±118 MBq.The diagnosis precision,sensitivity and specificity among these methods were compared.The relationship between radioactive uptake and clinical pathological stage of esophageal carcinoma was discussed by calculating the tumor to normal esophagus(T/N).Meanwhile,the integrin αvβ3 expression was assessed immunohistochemically in postoperative esophageal tissues.31 patients were diagnosed as esophageal carcinoma;and 1,leiomyosarcoma;and 6.leimyoma;and 2,esophageal tuberculosis.The accuracy,sensitivity and specificity of barium esophagography,endoscopic and SPECT/CT imaging are 92.5/93.8/87.5%,97.5/96.9/100%,and 90/90.6/87.5%,respectively.Abnormal accumulation of radiotracer in 29 malignant lesions is observed.The SPECT/CT imaging displayed the region of radioactive uptake and lesions matched extremely with the T/N ratio from 1.31 to 2.79(mean 2.04).A case with pulmonary metastases and a case with mediastinal lymph node metastases were found which were missed by barium esophagography and endoscopic.The99mTc-3P4-RGD2 uptake of the esophageal carcinoma masses had no relevance to the tumor pathologic classification(P>0.05).There was a significant positive correlation between T/N ratio and positive cell percentage of integrin αvβ3(r=0.976),demonst
99mTc-3PRGD2 is a new SPECT radiotracer for several tumor imaging with high uptake where integrinαvβ3 is highly expressed.This pilot study was to assess the safety,biodistribution and radiation dosimetry of 9,mTc-3PRGD2 in healthy volunteers.The 10 healthy male volunteers were injected with 99mTc-3PRGD2（786.7±55.8 MBq,19.1-24.2 mCi）.Baseline measurements of vital signs,laboratory safety tests and 12-lead electrocardiogram were recorded before and after injection.Blood and urine samples were collected and radiation counts were obtained at various time points.Whole-body scans and ROIs of identified organs were used for visual analysis and estimating the radiation dosimetry.No adverse reactions were found during the study.99mTc-3PRGD2 exhibited a rapid clearance from the blood with less than 45%of the initial dosage at 10 min after injection and gradual increasing radioactivity in urine with（52.9±6）%of original dose at 1440 min.The whole-body imaging showed high radioactive accumulation in bladder.And the highest 99mTc-3PRGD2 uptake was found in the kidneys(3.50×10-2 mSv/MBq).The 99mTc-3PRGD2 exhibited good pharmacokinetic properties and little radiation burden.This study showed that 99mTc-3PRGD2 would be a safe and attractive SPECT agent in clinic applications.
